These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37886555)

  • 21. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
    J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.
    Navarria P; Pessina F; Clerici E; Rossini Z; Franceschini D; D'Agostino G; Franzese C; Comito T; Loi M; Simonelli M; Lorenzi E; Persico P; Politi LS; Grimaldi M; Bello L; Santoro A; Fornari M; Servadei F; Scorsetti M
    J Neurosurg; 2020 Sep; 135(1):64-77. PubMed ID: 32886916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
    Incekara F; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Nandoe Tewarie R; Lycklama G; Vincent AJPE; Kros JM; Klein S; van den Bent M; Smits M
    Front Oncol; 2020; 10():596. PubMed ID: 32477929
    [No Abstract]   [Full Text] [Related]  

  • 24. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
    Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
    Kong DS; Kim HR; Choi YR; Seol HJ; Lee JI; Nam DH
    J Clin Neurosci; 2015 Sep; 22(9):1425-9. PubMed ID: 26138051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed
    Driscoll RK; Lyne SB; Voce DJ; Maraka S; Gondi V; Chmura SJ; Dixit KS; Kumthekar PU; Karrison TG; Pytel P; Collins JM; Stupp R; Merrell RT; Lukas RV; Yamini B
    Neurooncol Adv; 2024; 6(1):vdae014. PubMed ID: 38420615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotyping low-grade gliomas among Hispanics.
    Cardona AF; Rojas L; Wills B; Behaine J; Jiménez E; Hakim F; Useche N; Bermúdez S; Arrieta O; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; González D; Rodríguez J; Ortiz LD; Cifuentes H; Balaña C
    Neurooncol Pract; 2016 Sep; 3(3):164-172. PubMed ID: 31386063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma.
    Incekara F; Smits M; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Kros JM; Vincent AJPE; van den Bent M
    Front Oncol; 2020; 10():1087. PubMed ID: 32766140
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
    Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
    JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
    J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.